Assessing Cost-Effectiveness – Mental Health: introduction to the study and methods

References

• Gold M R, Siegel J E, Russell L B, Weinstein M C. Cost-effectiveness in health and medicine, M R Gold, J E Siegel, L B Russell, M C Weinstein. Oxford University Press, New York 1996
   Google Scholar
• Mathers C, Vos T, Stevenson C. The burden of disease and injury in Australia. Australian Institute of Health and Welfare, Canberra 1999, (Available at: http://www.aihw.gov.au/publications/)
   Google Scholar
• Vos T, Begg S. The Victorian Burden of Disease Study: morbidity. Public Health and Development Division, Department of Human Services, Melbourne 1999
   Google Scholar
• Nathan P E, Gorman J M. A guide to treatments that work, P E Nathan, J M Gorman. Oxford University Press, New York 1998
   Google Scholar
• Andrews G, Sanderson K, Slade T, Issakidis C. Why does the burden of disease persist? Relating the burden of anxiety and depression to effectiveness of treatment. Bulletin of the World Health Organization 2000; 78: 446–454
   PubMed Web of Science ®Google Scholar
• Carter R. The Macro Economic Evaluation Model (MEEM): an approach to priority setting in the health sector [PhD Thesis]. Monash University, Melbourne 2001
   Google Scholar
• Carter R, Stone C, Vos T, et al. Trial of program budgeting and marginal analysis (PBMA) to assist cancer control planning in Australia. Commonwealth Department of Health and Aged Care, Canberra 2000
   Google Scholar
• Australian Bureau of Statistics. Mental health and wellbeing: profile of adults, Australia 1997. Australian Bureau of Statistics, Canberra 1998
   Google Scholar
• Sawyer M G, Arney F M, Baghurst P A, et al. The mental health of young people in Australia. Mental Health and Special Programs Branch, Department of Health and Aged Care, Canberra 2000
   Google Scholar
• Jablensky A, McGrath J, Herrman H, et al. People living with psychotic illness: an Australian study 1997–1998. Department of Health and Aged Care, Canberra 1999
   Google Scholar
• Stouthard MEA, Essink-Bot M, Bonsel G J, et al. Disability weights for diseases in the Netherlands. Department of Public Health, Erasmus University, Rotterdam 1997
   Google Scholar
• Deeks J J, Altman D G, Bradburn M J. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. Systematic reviews in health care: meta-analysis in context, 2nd edn., M Egger, G D Smith, D G Altman. BMJ Publishing Group, London 2001; 285–312
   Google Scholar
• National Health and Medical Research Council. How to use the evidence: assessment and application of scientific evidence. National Health and Medical Research Council, Canberra 2000
   Google Scholar
• Gould R A, Otto M W, Pollack M H. A meta-analysis of treatment outcome for panic disorder. Clinical Psychology Review 1995; 15: 819–844
   Web of Science ®Google Scholar
• Rosenthal R. Meta-analytic procedures for social research. SAGE, Newbury Park, CA 1991
   Google Scholar
• Egger M, Smith G D, Altman D G. Systematic reviews in health care: meta-analysis in context, 2nd edn., M Egger, G D Smith, D G Altman. BMJ Publishing Group, London 2001
   Google Scholar
• The Quality Assurance Project. A treatment outline for depressive disorders. Australian and New Zealand Journal of Psychiatry 1983; 17: 129–146
   PubMed Web of Science ®Google Scholar
• Hróbjartsson A, Gøtzsche P C. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. New England Journal of Medicine 2001; 344: 1594–1602
   PubMed Web of Science ®Google Scholar
• Sanderson K, Andrews G, Corry J, Lapsley H. Using the effect size to model change in preference values from descriptive health states. Quality of Life Research 2004; 13, in press
   PubMedGoogle Scholar
• Ormel J, von Korff M, van den Brink W, Katon W, Oldehinkel T. Depression, anxiety, and social disability show synchrony of change in primary care patients. American Journal of Public Health 1993; 83: 385–390
   PubMed Web of Science ®Google Scholar
• Chouinard G, Albright P S. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology 1997; 17: 298–307
   PubMed Web of Science ®Google Scholar
• Drummond M F, O'Brien B, Stoddart G L, Torrance G W. Methods for the economic evaluation of health care programmes, 2nd edn. Oxford University Press, Oxford 1997
   Google Scholar
• Australian Institute of Health and Welfare. Health expenditure Australia 2000–01. Australian Institute of Health and Welfare, Canberra 2002, Health and Welfare Expenditure Series no.14
   Google Scholar
• Palisade Corporation. @RISK [computer program] Risk Analysis Add-in for Microsoft Excel. Palisade Corporation, Newfield, NY 2001, Version 4
   Google Scholar
• Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada, 2nd edn. Canadian Coordinating Office for Health Technology Assessment (CCOHTA, Ottawa 1997
   Google Scholar
• Deeks J J. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine 2002; 21: 1575–1600
   PubMed Web of Science ®Google Scholar
• Gureje O, Herrman H, Harvey C, Trauer T, Jablensky A. Defining disability in psychosis. Performance of the diagnostic interview for psychosis-disability module (DIP-DIS) in the Australian National Survey of Psychotic Disorders. Australian and New Zealand Journal of Psychiatry 2001; 35: 846–851
   PubMed Web of Science ®Google Scholar
• Richardson J, Olsen J, Hawthorne G, Mortimer D, Smith R. The measurement and valuation of utility based quality of life: Recommendations from a review of the literature. CHPE Working Paper. Centre for Health Program Evaluation, Melbourne 1999
   Google Scholar